A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2015
At a glance
- Drugs RO 5545965 (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Roche
- 14 Oct 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 11 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.
- 04 Aug 2014 Planned End Date changed from 1 May 2014 to 1 Aug 2014 as reported by ClinicalTrial.gov.